Efficacy and safety profile of roflumilast in a real-world experience
نویسندگان
چکیده
منابع مشابه
Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience
AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting. METHODS We performed a retrospective analysis of treatment outcomes among treatment-naïve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [t...
متن کاملEfficacy and Safety of Roflumilast in Korean Patients with COPD
PURPOSE Roflumilast is the only oral phosphodiesterase 4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD) patients [post-bronchodilator forced expiratory volume in 1 second (FEV₁) <50% predicted] with chronic bronchitis and a history of frequent exacerbations. This study evaluated the efficacy and safety of roflumilast in Korean patients with COPD and compared the effica...
متن کاملa comparison of teachers and supervisors, with respect to teacher efficacy and reflection
supervisors play an undeniable role in training teachers, before starting their professional experience by preparing them, at the initial years of their teaching by checking their work within the proper framework, and later on during their teaching by assessing their progress. but surprisingly, exploring their attributes, professional demands, and qualifications has remained a neglected theme i...
15 صفحه اولa study of the fifth child and ben in the world by doris lessing in the light of julia kristevas psychoanalytic concepts
این مطالعه به بررسی عوامل روانشناختی کریستوادردو رمان دوربس لسینگ،فرزندبنجم و بن دردنیای واقعی می بردازد.موفقیت یا شکست کاراکترهادر تکمیل شکست تتیزی یه کمک بدر وهم از مهم ترین دغدغه محقق می باشد.به بررسی تحلیل روانشناختی تمامی کاراکترها خصوصا بن برداخته و به دنبال نشانه هایی از جامعه شیشه ای کریستوا می باشد.
15 صفحه اولCardiovascular safety of roflumilast.
In this issue of CHEST (see page 758), White et al 1 report signifi cantly lower major adverse cardiovascular events (MACEs) for rofl umilast compared with placebo (hazard ratio, 0.65; 95% CI, 0.45-0.93; P 5 .019) from data in 12,054 patients with COPD. In addition to the studies analyzed not being designed or powered to examine cardiovascular outcomes, we would like to point out other limitati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Disease
سال: 2019
ISSN: 2072-1439,2077-6624
DOI: 10.21037/jtd.2019.04.49